Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial

Blood. 2017 Sep 21;130(12):1477-1480. doi: 10.1182/blood-2017-04-775841. Epub 2017 Jul 17.

Authors

Isabelle Krämer¹, Stephan Stilgenbauer², Sascha Dietrich¹, Sebastian Böttcher^{3

4}, Matthias Zeis⁵, Michael Stadler⁶, Jörg Bittenbring⁷, Lutz Uharek⁸, Christof Scheid⁹, Ute Hegenbart¹, Anthony Ho¹, Michael Hallek⁹, Michael Kneba³, Norbert Schmitz⁵, Hartmut Döhner², Peter Dreger¹

Affiliations

¹ Department of Medicine V, University of Heidelberg, Heidelberg, Germany.
² Department of Medicine III, University of Ulm, Ulm, Germany.
³ Department of Medicine II, University of Schleswig-Holstein, Kiel, Germany.
⁴ Department of Medicine III, University Medical Center Rostock, Rostock, Germany.
⁵ Department of Hematology, Oncology, and Stem Cell Transplantation, Asklepios Hospital St. Georg, Hamburg, Germany.
⁶ Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
⁷ Department of Internal Medicine I, Saarland University Medical School, Homburg, Germany.
⁸ Division of Hematology, Oncology, and Tumor Immunology, Charité University Medicine Berlin, Berlin, Germany; and.
⁹ Department of Medicine I, University of Cologne, Cologne, Germany.

PMID: 28716861
DOI: 10.1182/blood-2017-04-775841

No abstract available

Publication types

Clinical Trial
Letter
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Adult
Aged
Alemtuzumab / therapeutic use
Allografts
Antineoplastic Agents, Immunological / therapeutic use
Combined Modality Therapy
Disease-Free Survival
Female
Follow-Up Studies
Graft vs Host Disease / epidemiology
Graft vs Host Disease / etiology
Humans
Kaplan-Meier Estimate
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
Male
Middle Aged
Molecular Targeted Therapy
Neoplasm, Residual
Peripheral Blood Stem Cell Transplantation* / statistics & numerical data
Piperidines
Prognosis
Pyrazoles / therapeutic use
Pyrimidines / therapeutic use
Salvage Therapy
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Alemtuzumab
Adenine